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Abbreviations
BOC : boceprevir
DAA : direct-acting antiviral agent
(e)RVR : (extended) rapid virological response
ETR : end-of-treatment response
HCV : hepatitis C virus
IL28B : interleukin-28B gene
LLOD : lower limit of detection
LLOQ : lower limit of quantification
pegIFN : pegylated interferon
RBV : ribavirin
RGT : response-guided therapy
RNA : ribonucleic acid
RVR : rapid virological response
SNP : single nucleotide polymorphism
SOC : standard of care
SVR : sustained virological response
TVR : telaprevir
Introduction
Chronic hepatitis C virus (HCV) affects approximate-
ly 170 million people worldwide. Hepatitis C virus-
induced cirrhosis remains the most common indication
for liver transplantation and is a major contributor to the
worldwide increase in the incidence of hepatocellular
cancer (1). Among the six major genotypes, genotype 1
is the most common and difficult to treat. Treatment for
this disease has consisted of therapies that stimulate the
immune system and interfere in a nonspecific manner
with viral replication. For the past decade, the standard
of care for patients with chronic infection with genotype
1 HCV has been 48-week treatment of pegylated inter-
feron (pegIFN) alfa and ribavirin (RBV). The observed
rates of sustained virological response (SVR) with
pegIFN and RBV therapy are 40-50% (2-5). Research
has focused on therapies that inhibit HCV proteins that
are essential for intracellular replication. These drugs are
referred to as direct-acting antiviral agents (DAAs).
Currently, boceprevir and telaprevir, which are 2 first-
generation DAAs, are available for the treatment of
genotype 1 chronic hepatitis C. These guidelines update
the existing BASL guidelines (6) for the treatment of
genotype 1 chronic hepatitis C. The current recommen-
dations are based on published data of these new mole-
cules published prior to 31 March 2012.
HCV life cycle and first-generation DAAs
HCV is an enveloped single-strand RNA virus that
mainly targets hepatocytes. It enters cells through a mul-
tistep process that requires the interaction of the HCV
envelope glycoproteins E1 and E2 and a variety of cell-
surface receptors, which most likely include low-density
lipoproteins receptors (7).
After entering the hepatocyte, HCV uncoats in a pH-
dependent manner. The sense single-stranded RNA
genome is used as a direct template for translation. The
ribosomes assemble on the internal ribosomal entry site
at the 5' end of the viral genome. Translation results in a
unique open reading frame which encodes for a polypro-
tein of approximately 3000 amino acids. This polypro-
tein is divided into mature proteins by host cell proteas-
es and the HCV nonstructural (NS) 2 and NS3 (together
with its cofactor NS4A) proteases. The activity of the
NS3/4A protease is inhibited by boceprevir (BOC) and
telaprevir (TVR). After processing by cellular and viral
proteases, the following 10 different proteins are
formed : the core and the 2 envelope proteins form the
structure of the virion whereas the others nonstructural
proteins participate in the viral life cycle (Fig. 1) (8,9).
The NS5B RNA-dependent RNA polymerase and the
NS3 helicase are necessary for HCV RNA replication.
Sense RNA strands are copied into antisense strands in a
cyclophilin B- and microRNA 122-dependent fashion.
This antisense strand then becomes a template for
 producing many sense RNA strands. Each of these steps
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followed by one of 3 different treatment regimens (16).
In the first group, triple therapy [pegIFN-RBV+ BOC
(800 mg tid taken with food and with a 7- to 9-hour inter-
val between doses)] was administered for a treatment
period based on the week 8 HCV RNA level [response-
guided therapy (RGT)]. If the HCV RNA level at week 8
was undetectable (i.e., after a 4-week lead-in period and
4 weeks of triple therapy, defined in this study as RVR)
and maintained during therapy [extended RVR (eRVR)]
all therapy was discontinued at week 28 ; if the HCV
RNA level was detectable at week 8 (and undetectable at
week 28 otherwise there was a nonresponse), BOC was
discontinued at week 28 and SOC was continued for 20
more weeks. In the second arm, BOC-pegIFN-RBV
triple therapy was given for a fixed duration of 44 weeks.
The third arm received SOC for 44 weeks. The overall
SVR rates for treatment arms 1-3 were 63%, 66% and
38%, respectively, which demonstrated a significantly
higher efficacy of the BOC triple therapy compared with
the SOC treatment (Table 1). The SVR rates were signif-
icantly higher in Caucasians compared with blacks. The
presence of eRVR was associated with an SVR 85-90%
in all treatment arms independent of race. Advanced
fibrosis (9% of patients) was associated with lower SVR
rates.
BOC is licensed in the EU for the treatment of  chronic
hepatitis C in patients with compensated liver disease and
who are treatment naïve. All patients should be treated
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engages an error-prone polymerase that produces a set of
diverse virions by each infected cell. As a result, virion
production increases HCV quasispecies.
Finally, newly produced viral RNA genomes are
packaged ; viral core particles are assembled on lipid
particles, and new virions are generated. This process
appears to be closely associated with LDL (10-12).
DAA in naïve genotype 1 patients
The response to the pegIFN and RBV bitherapy stan-
dard of care (SOC) is described using the following def-
initions (13-15) : sustained virological response (SVR)
indicates an undetectable HCV RNA level at 24 weeks of
treatment completion ; rapid virological response (RVR)
indicates an undetectable HCV RNA level at 4 weeks of
treatment that is maintained until the treatment has been
completed [extended RVR (eRVR)] ; early virological
response (EVR) indicates a detectable HCV RNA level
at week 4 but undetectable at week 12. Based on phase
III trial results, BOC and TVR, which are HCV nonstruc-
tural protein 3/4A (NS3/4A) serine protease inhibitors,
are the first licensed DAAs for the treatment of chronic
hepatitis C.
BOC was evaluated in the SPRINT-2 trial. All patients
received a 4-week lead-in treatment of pegIFN alfa-2b
(1.5 µg/kg body weight once weekly) and RBV (600-
1400 mg/d based on body weight) bitherapy, which was
Fig. 1. — HCV life cycle
Reprinted with permission From WB Saunders Clinics in Liver Disease : An overview of emerging therapies for the treatment of
chronic hepatitis C by Ilyas J.A. and Vierling J.M. (9).
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with a 4-week lead-in period with pegIFN alfa (unspeci-
fied whether -2a or -2b) and RBV, which is followed by
BOC-pegIFN-RBV tritherapy. If patients do not have
cirrhosis and achieve undetectable HCV RNA levels at
weeks 8 and 24, treatment is discontinued after a total
duration of 28 weeks. In non-cirrhotic patients with a
detectable HCV RNA level at week 8 but an undetectable
HCV RNA level at week 24, triple therapy is to be con-
tinued through week 36, followed by pegIFN-RBV
bitherapy until week 48. In patients with cirrhosis, triple
therapy is to be given for 44 weeks (although, at least in
Caucasians, SVR rates in patients with metavir F3-4
were comparable between RGT and fixed duration treat-
ment).
TVR was evaluated in two phase III trials. In the
ADVANCE trial, patients received pegIFN alfa-2a (180
µg once weekly), RBV (1000-1200 mg/d based on body
weight) and TVR (750 mg tid taken with food and with
an 8-hour interval between doses) for 8 or 12 weeks, fol-
lowed by the SOC treatment in a RGT strategy based on
eRVR (undetectable HCV RNA levels at weeks 4 and
12). In the case of eRVR, therapy was discontinued at
week 24 ; if eRVR did not occur, SOC treatment was
continued for 48 weeks (17). Overall SVR rates were
69% (TVR 8 weeks) and 75% (TVR 12 weeks) com-
pared with 44% in patients receiving SOC treatment
(Table 1). eRVR was the strongest predictor of SVR. The
SVR rates were lower in blacks and in patients with
advanced fibrosis but also in these difficult-to-treat
groups, the SVR rates were significantly higher in the
TVR-treated groups.
In the ILLUMINATE study, all patients received a 12-
week course of pegIFN alfa-2a-RBV-TVR triple therapy,
with further RGT based on eRVR (18). In case of eRVR,
SVR rates were 92% and 88% for the 24- and 48-week
treatment regimens, respectively. The patients who did
not achieve eRVR were treated for 48 weeks with an
SVR rate of 68%. In patients with cirrhosis who
achieved eRVR, the SVR rate was only 61% in those
treated for 24 weeks compared with 92% in cases of 48
weeks of treatment.
TVR is licensed in the EU for the treatment of chron-
ic hepatitis C in patients with compensated liver disease
(including cirrhosis) who are treatment naïve. There is
no lead-in period. Triple therapy [i.e., TVR, pegIFN alfa
(unspecified whether -2a or -2b) and RBV] should be
administered for 12 weeks, followed by the SOC treat-
ment. In patients without cirrhosis, the treatment dura-
tion depends on HCV RNA levels at weeks 4 and 12. If
the HCV RNA levels are undetectable at weeks 4 and 12,
treatment can be discontinued at 24 weeks. Otherwise,
treatment should be continued for 48 weeks. The patients
with cirrhosis should be treated for 48 weeks regardless
of the HCV RNA level at week 4.
The EMA licenses for TVR and BOC allow cotreat-
ment with pegIFN alfa-2a and -2b, which are both
 commercially available. The data on BOC treatment are
primarily with pegIFN alfa-2b and TVR with pegIFN
alfa-2a. More severe neutropenia is reported with
BOC/pegIFN alfa-2a bitherapy, whereas more frequent
viral breakthrough is noted in the TVR/pegIFN alfa-2b
combination therapy. However, the data are limited and
should be interpreted with caution.
DAA in treatment-experienced patients 
Treatment-experienced patients are patients who did
not achieve SVR in a previous course of treatment and
might be either experiencing breakthrough or are
relapsers, partial responders or null responders (13,14).
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Table 1. — SVR rates with first-generation DAAs in naïve patients
The sustained viral response rates of boceprevir and telaprevir in treatment-naïve patients. The
results (sustained viral response rates expressed in % in an intention-to-treat analysis) are shown
for boceprevir in the SPRINT-2 trial (16) and for telaprevir in the ADVANCE trial (17) for
 different categories of patients. BOC = boceprevir ; SOC = standard of care ; RGT = response-
guided therapy ; F = metavir fibrosis stage ; eRVR = extended rapid virological response ;
- = absent ; + = present ; and TVR = telaprevir.
BOC
SPRINT-2
Overall Caucasian/black F0-2/F3-4 eRVR-/+
SOC 38 40/23 38/38 30/85
BOC, RGT 63 67/42 67/41 36/88
BOC, fixed duration 66 68/53 67/52 40/90
TVR
ADVANCE
Overall Caucasian/black F0-2/F3/F4 eRVR-/+
SOC 44 48/25 49/35/38 42/93
TVR, 8 weeks 69 73/58
TVR, 12 weeks 75 79/62 82/63/71 60/92
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decline from the baseline from week 12 of pegIFN-RVR
bitherapy of 4 BOC studies were allowed to participate
in a roll over study (PROVIDE) with a 4-week lead-in
period of pegIFN-RBV and 44 weeks of pegIFN-RBV-
BOC. An SVR rate of 38% was achieved (20). Because
this was a single-arm study, this result cannot be used for
a direct comparison with other treatment regimens.
In the EU, BOC is licensed for the treatment of chron-
ic hepatitis C patients with compensated liver disease
who have failed previous treatment. In previous null
responders, only the 48-week fixed duration treatment
schedule (i.e., a 4-week lead-in period and 44 weeks of
triple therapy) is approved. In other treatment-experi-
enced patients, the approved treatment regimen consists
of a 4-week lead-in period with the SOC treatment, triple
therapy until week 36 and finally, the SOC treatment
until week 48. The EMA label specifically mentions null
responders ; although, they were excluded in the phase
III trial. Contrary to the registration study, FDA label and
AASLD recommendations, RGT for previous relapsers
or partial responders is not in the EMA BOC registration
label, which instructs physicians to continue the SOC
treatment from weeks 36 to 48 to minimize relapse rates
for patients who belong to this response category.
The REALIZE phase III TVR trial for treatment-
experienced genotype 1 patients included 662 patients
with prior null or partial response or relapse ; therefore,
true null responders were included. Patients with cirrho-
sis could be included in the study and constituted 26% of
the patient population.
The patients were treated with pegIFN alfa-2a (180 µg
once weekly), RBV (1000-1200 mg/d based on body
weight) and TVR (750 mg tid taken with food and with
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Breakthrough corresponds to the reappearance of HCV
RNA at any time during the treatment after initial virolog-
ical response. Relapse indicates that patients achieved an
undetectable HCV RNA level at the end of treatment,
end-of-treatment response (ETR), with a subsequent
reappearance of HCV RNA. Partial response is defined as
more than a 2 log10 decrease from the baseline but still
detectable HCV RNA levels at weeks 12 and 24 ; null
response indicates a less than 2 log10 decrease from base-
line in the HCV RNA level at week 12. Nonresponders
consist of patients having a null response or a partial
response.
The RESPOND-2 phase III boceprevir trial for treat-
ment-experienced genotype 1 patients included 403
treated patients with prior nonresponse (64.3%) or
relapse (35.7%) status (19). Nonresponse was defined as
at least a 2 log10 decrease from baseline in the HCV RNA
level by week 12 but a detectable HCV RNA level dur-
ing the therapy period, thereby including only partial
responders but excluding null responders. The patients
with cirrhosis could be included and constituted 12% of
the patient population.
The patients were treated with pegIFN alfa-2b
(1.5 µg/kg body weight once weekly), RBV (600-
1400 mg/d based on body weight) and BOC (800 mg tid
taken with food and with a 7- to 9-hour interval between
doses) vs. placebo according to three different treatment
regimens. In all three groups, the patients were treated
with pegIFN and RBV bitherapy for the first 4 weeks
(lead-in phase). The first group continued bitherapy for
44 more weeks and constituted the control group who
received the standard of care (SOC) treatment. Group 2
received triple therapy for 32 weeks. Based on the HCV
RNA levels at weeks 8 and 12, patients either discontinued
treatment at week 36 (if undetectable HCV RNA levels at
weeks 8 and 12) or continued pegIFN-RBV bitherapy
until a total treatment duration of 48 weeks (if a detectable
HCV RNA level at week 8 but undetectable at week 12)
(RGT). The third group received tritherapy for 44 weeks.
The SVR rates were 21%, 59% and 66% for treatment
arms 1-3. Triple therapy with BOC is clearly superior to
the SOC treatment in treatment-experienced patients.
The patients achieving eRVR had an SVR rate of 89%.
Forty-six percent of the patients were eligible for a short-
er treatment period in the RGT arm. Overall SVR rates
were, however, not higher in the RGT arm vs. the fixed-
treatment arm, and in patients with cirrhosis, the SVR
rate was significantly lower in the RGT arm (35% vs.
77%). SVR rates were significantly different according
to the previous treatment responses ; relapsers experi-
enced significantly higher SVR rates compared with par-
tial responders (Table 2). High viral load at baseline and
the presence of cirrhosis were also predictors of lower
SVR. A week-4 response defined as a > 1 log10 decline in
the HCV RNA level from the baseline was also a strong
predictor of response.
True null responders were excluded in the
RESPOND-2 trial. Null responders, defined as < 2 log10
Table 2. — SVR rates with first-generation DAAs in
 treatment-experienced patients
The sustained viral response rates of boceprevir and telaprevir in
treatment-experienced patients. The results (sustained virological
response rates expressed in % in an intention-to-treat analysis) are
shown for boceprevir in the RESPOND-2 trial (19) and for telaprevir
in the REALIZE trial (21) for different categories of previous treatment
response. * = 38% in the PROVIDE study (20). BOC = boceprevir ;
SOC = standard of care ; RGT = response-guided therapy ; TVR =
telaprevir ; and NA = not applicable.
BOC
RESPOND-2
Relapser Partial responder Null responder
SOC 29 7 NA
BOC, RGT 69 40 NA
BOC, fixed duration 75 52 NA*
TVR
REALIZE
Relapser Partial responder Null responder
SOC 24 15 5
TVR 83 59 29
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an 8-hour interval between doses) vs. placebo treatment
according to three different treatment regimens as fol-
lows : in the first arm, patients received 12 weeks of
triple therapy, followed by a 36-week SOC treatment ; in
the second arm, a 4-week lead-in period of the SOC
treatment was followed by 12 weeks of triple therapy
and finally followed by a 32-week SOC treatment ; and
the third arm consisted of a 48-week SOC treatment (21).
SVR rates were 64, 66 and 17%, respectively for
treatment arms 1-3. Triple therapy with TVR is clearly
superior to the SOC in treatment-experienced patients.
The SVR rates were significantly different according to
previous treatment response ; the SVR rates were signif-
icantly higher in the relapsers compared with the partial
responders. Compared with relapsers and partial respon-
ders, prior null responders had the lowest SVR rates
(Table 2). The presence of cirrhosis negatively influ-
enced SVR rates in partial responders and null respon-
ders. The presence of a lead-in period did not lead to
increased SVR rates (21).
In the EU, TVR is licensed for the treatment of chron-
ic hepatitis C genotype 1 patients with compensated liver
disease (including cirrhosis) who have failed previous
therapy, i.e., specified as relapsers, null responders and
partial responders. RGT is licensed for the treatment of
relapsers without cirrhosis based on phase II data ; in
cases of eRVR (i.e., defined as undetectable HCV RNA
levels at week 4s and 12) treatment can be discontinued
after 24 weeks (18). In all other cases, only the 48-week
fixed duration treatment schedule (i.e., 12 weeks of triple
therapy and 36 weeks of pegIFN-RBV bitherapy) is
approved. The AASLD guidelines suggest that response-
guided therapy could be considered for prior partial
responders, but this is not included in the EMA TVR
 registration label.
Virological follow-up
First-generation protease inhibitor-based triple thera-
py induces a rapid, efficacious viral suppression that can
lead to higher SVR rates if adequate viral suppression is
maintained throughout treatment. These protease
inhibitors yield higher SVRs ; however, the potential for
developing resistance is a disadvantage of their use. The
proper use of HCV RNA assays is essential for manag-
ing hepatitis  C treatment in the DAA era. HCV RNA
monitoring at predefined time allows the physician to
correctly apply response-guided therapy and futility
rules. RGT determines whether a genotype 1 patient is
eligible for therapy of a shortened duration. If the decline
in the viral load is suboptimal, futility rules provide
instruction on when to discontinue therapy, which mini-
mizes the risk of resistance and avoids futile exposure to
unnecessary adverse events because the patient will have
no opportunity to achieve SVR.
The lower limit of detection (LLOD) of an HCV RNA
assay is distinct from the lower limit of quantification
(LLOQ). The LLOQ is the lowest HCV RNA concentra-
tion within the linear range of the assay ; i.e., the LLOQ
is the smallest amount of HCV RNA that can be detect-
ed and accurately quantified. The LLOD is the lowest
amount of HCV RNA concentration that can be detected
with 95% probability to determine the presence or
absence of the virus. Quantitative assays are required to
make on treatment decisions. The same assay should be
used when treating a patient to ensure that the results can
be applied consistently during the course of therapy.
Quantitative HCV RNA assays with an LLOQ of less
than or equal to 25 IU/mL and an LLOD of approximate-
ly 10-15 IU/mL should be used when managing patients
who receive TVR- or BOC-based triple therapy.
Response-guided therapy
With TVR, noncirrhotic treatment-naïve patients and
previous relapsers can qualify for RGT if they have an
undetectable HCV RNA level at week 4 of triple therapy,
i.e., an RVR that is maintained at week  12 of therapy
(eRVR). This eRVR criterion is maintained in the major-
ity of ongoing clinical trials with next-generation DAAs.
The time points for considering RGT with BOC differ
because of the 4-week lead-in period, prior to the initia-
tion of boceprevir. With BOC, noncirrhotic treatment-
naïve patients can qualify for RGT if they have an unde-
tectable HCV RNA level at week 8, which is week 4 of
a triple therapy, that is maintained at week 24 of therapy.
Futility rules
For telaprevir-treated patients, therapy should be dis-
continued at either weeks 4 or 12 if the viral load is
> 1,000 IU/mL or detectable at treatment week 24 with
an assay using an LLOD of approximately 10-15 IU/ml.
For boceprevir, therapy should be discontinued at week
12 if the viral load is > 100 IU/mL or detectable at treat-
ment week 24 with an assay using an LLOD of approxi-
mately 10-15 IU/ml. It is advisable to verify HCV RNA
levels similarly at week 36 with an assay using an LLOD
of approximately 10-15 IU/ml in patients requiring a 48-
week treatment period.
ETR is defined as an undetectable HCV RNA level at
the end of treatment with an assay using an LLOD of
approximately 10-15 IU/ml.
Previously, sustained virological response (SVR) to
pegIFN and ribavirin was defined as the absence of
detectable HCV RNA serum levels at 6 months after the
end of therapy using an assay with a sensitivity of at least
50 IU/mL. This definition has recently been revised by
the FDA in the telaprevir and boceprevir package inserts
and at 6 months after the end of treatment, specifies an
HCV RNA level that is less than 25 IU/ml.
The distinction between a detectable and an unde-
tectable HCV RNA result is important when considering
treatment truncation. An undetectable HCV RNA level
on treatment is required to qualify for response-guided
therapy. An unjustified shortening of the treatment
 duration in patients who have HCV RNA levels below
Acta Gastro-Enterologica Belgica, Vol. LXXV, April-June 2012
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week treatment duration. The HCV RNA monitoring
times are as follows : at baseline, treatment weeks 4, 12
and 24, week-24 follow-up post treatment and weeks 36
and 48 in patients requiring a 48-week treatment. For
boceprevir-treated patients, an additional HCV RNA
assay should be performed at week 8, which is optional
for telaprevir-treated patients.  The week-4 HCV RNA
level after the lead-in period prior to the initiation of
boceprevir provides interesting information concerning
the interferon response.
Resistance
Because of the high replication turnover of the
 hepatitis C virus and the low fidelity of its NS5B poly-
merase, numerous variants, termed quasispecies, are
Acta Gastro-Enterologica Belgica, Vol. LXXV, April-June 2012
the limit of quantification but are still confirmed
detectable at weeks 4 or 12 with telaprevir triple therapy
or at week 8 in the case of boceprevir, would compro-
mise the probability of achieving an SVR because a full
48-week course of therapy is required in such patients to
increase ETR and minimize relapse rates (22). All thera-
py should be discontinued in patients who have HCV
RNA levels below the limit of quantification but are con-
firmed detectable at weeks 24 or 36 because of futility.
These concepts are represented schematically in Fig. 2.
From the abovementioned details, it is evident that
older qualitative HCV RNA assays with an LLOD of
50 IU/ml cannot be used for the appropriate monitoring
of patients treated with telaprevir- or boceprevir-based
triple therapy. The number of assays required to monitor
patients is 5 to 8 depending on a shortened or full 48-
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continuously generated in an infected patient (23). In the
absence of complete suppression, DAA may select for
pre-existing variants with decreased DAA susceptibility,
which may be associated with treatment failure (24). In
the phase 1b trials, BOC and TVR monotherapy selected
for a large number of mutational variants in the catalytic
domain of the NS3 protease (25,26). Mutations at 6
amino acid positions (i.e., V36, T54, V55, R155, A156,
and V170) were associated with resistance to these pro-
tease inhibitors. The addition of pegIFN alfa and RBV to
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Table 3. — Drug-drug interactions
Class of medication Interaction with BOC Interaction with TVR
LIPID LOWERING DRUGS
Atorvastatin  
Fibrates  
Lovastatin  
Pravastatin  
Rosuvastatin  
Simvastatin  
ANTIARRHyTmICS
Amiodarone  
Digoxin  
Flecainide  
Lidocaine  
Quinidine  
CONTRACEPTIVES
Ethinylestradiol  
Norethisterone  
ANTICOAGULANTS
Warfarin  
Dabigatran  
ANTIDEPRESSANTS
Citalopram  
Escitalopram  
Mirtazepine  
Sertraline  
ANXIOLyTICS/HyPNOTICS
Diazepam  
Lorazepam  
Midazolam (oral)  
Midazolam (parenteral)  
Zolpidem  
ANTIBIOTICS
Azithromycin  
Ciprofloxacin  
Clarithromycin  
Erythromycin  
Moxifloxacin  
Ofloxacin  
Tetracyclins  
Trimethoprim/sulfamethoxazole  
ANTI-EPILEPTIC DRUGS
Carbamazepine  
Levetiracetam  
Phenytoin  
Valproate  
ANTI-RETROVIRAL DRUGS
Aztanavir  
Indinavir  
Lopinavir  
Ritonavir  
Saquinavir  
ImmUNE SUPPRESSIVES
Azathioprine  
Ciclosporin  
Tacrolimus  
Budesonide  
Methylprednisolone  
 Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration.
 Should not be coadministered.
 No clinically significant interaction expected.
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every 8 hours) regimen is required to maintain the mini-
mum drug levels to suppress HCV RNA levels and to
reduce the chance of breakthrough. Minimizing the
development of compensatory mutations involves early
discontinuation of therapy when antiviral therapy is
unlikely to succeed, i.e., the above mentioned futility
rules.
IL28B polymorphism and DAA
Single nucleotide polymorphisms (SNPs) in the
region of the interleukin-28B (IL28B) gene have been
associated with spontaneous and pegIFN-ribavirin com-
bination treatment-induced clearance of HCV infec-
tion (36-38). The SNPs are located near the IL28B gene
on chromosome 19, which implicates a role for its gene
product, interferon-λ3, in the immune response to HCV.
The predictive value of pretreatment IL28B rs12979860
genotype testing for SVR is superior to that of the pre-
treatment HCV RNA level, fibrosis stage, age, and sex in
genotype 1 chronic hepatitis C patients. On-treatment
rapid viral response within the first 4 weeks of treatment
initiation is the strongest predictor of SVR, irrespective
of the IL28B genotype (39-41). 
An analysis of the BOC- and TVR-treated patient sub-
groups with available IL28B rs12979860 genotyping
who were treated in the phase 3 studies exhibited higher
SVR rates in CC patients compared with CT/TT
patients (42,43). BOC- and TVR-based triple therapy
increased SVR rates across all rs12979860 genotypes in
most of the subanalyses. The patients achieving RVR
who qualify for shortened response-guided therapy more
often belonged to the baseline rs12979860 CC genotype
subgroup. Although the IL28B genotype provides infor-
mation regarding the probability of SVR and abbreviat-
ed therapy, there are insufficient data to support with-
holding protease inhibitor therapy from persons with the
favorable CC genotype because of the potential to abbre-
viate therapy and the trend for higher observed SVR
rates. The role of baseline IL28B genotype testing will
likely disappear upon the availability of more potent sec-
ond-generation protease inhibitors and combination ther-
apies of different classes of DAAs, guided by on-treat-
ment viral kinetics.
Pharmacokinetics and Drug-Drug interactions
BOC is rapidly absorbed and eliminated (mean plas-
ma half-life of 3-5 hours). Given the fact that food sig-
nificantly increases the bioavailability of BOC (40%-
60%) regardless of fat content, BOC should be adminis-
tered with meals. Once absorbed, it is metabolized pri-
marily by aldo-keto reductase and to a lesser degree by
CYP3A4/5 enzymes. BOC and its metabolites are elimi-
nated primarily by hepatic clearance. Special population
studies concluded that no dose adjustment was required
for subjects with mild or moderate hepatic impairment or
with renal impairment. BOC is eliminated predominant-
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a protease inhibitor significantly increased antiviral
activity, lowered relapse rates, and reduced viral break-
through and the emergence of resistance (27-30).
Nevertheless, in the vast majority of patients who failed
to eradicate HCV infection on protease inhibitor-based
triple therapy, the dominant viral population at the time
of breakthrough or relapse was resistant to the adminis-
tered protease inhibitor.
Resistance to BOC occurs more frequently in patients
with a < 1 log10 of HCV RNA at the end of the 4-week
lead-in period with pegIFN and RBV. Not surprisingly,
this occurred more frequently in the population of previ-
ous nonresponders. Resistance to TVR was equally
observed in nonresponder patients who were retreated
with TVR-based triple therapy. Selection of resistant
variants to both BOC and TVR with associated viral
breakthrough have been observed more frequently in
patients infected with HCV subtype 1a compared with
subtype 1b (31,32). For the main resistance variant
R155K, only 1 nucleotide substitution is required for
subtype 1a HCV, whereas 2 changes are required to gen-
erate the same amino acid substitution for subtype 1b
HCV (33).
Follow-up studies have shown that these variants can
progressively disappear and be replaced by the wild-type
virus within months in some patients but remain present
in other patients (18,34,35). The apparent disappearance
of BOC- or TVR-resistant variants in a treated patient
does not indicate that these variants have been cleared. It
is more likely that the resistant variants remain as minor
viral populations that replicate at low levels and cannot
be detected by techniques such as population sequenc-
ing. The potential persistence of selected resistant vari-
ants in patients with treatment failure could affect future
treatment options for the next generation protease
inhibitors because of cross-resistance.
BOC and TVR, which are two currently licensed first-
generation protease inhibitors, have short half-lives.
Therefore, strict adherence with the frequent dosing (i.e.,
Table 4. — First-generation DAA : DONT’s
Do not Reason
Prescribe boceprevir or telaprevir
to a non-genotype 1 HCV patient
Unlabeled, generally unproved
efficacy
Prescribe boceprevir or telaprevir
in monotherapy
Rapid development of resistance
Initiate boceprevir or telaprevir +
pegIFN without ribavirin
Reduced efficacy, risk of
 resistance
Reinitiate boceprevir or telapre-
vir once discontinued
Risk of resistance
Reduce dose of boceprevir or
telaprevir
Risk of resistance
Retreat with another first-
 generation DAA in case of viro-
logical failure
Cross-resistance
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ly in the feces (approximately 80%) with lesser amounts
eliminated in the urine (approximately 9%) (16,44,45).
TVR is also rapidly absorbed and has a half-life of
1 hour (45, 46) and is absorbed by the liver on first-pass
metabolism, which results in high liver concentrations.
Systemic TVR exposure was increased by 237% when
TVR was administered with a standard fat meal com-
pared with a fasting state, which indicates the need of
intake with a fatty snack (i.e., at least 20 grams of fat
content). TVR is extensively metabolized in the liver,
primarily by cytochrome P450 CYP3A4. Elimination is
predominantly in the feces (approximately 80%) with
minimal renal elimination (approximately 1%) (45-47).
Because TVR and BOC are both the substrate and
inhibitor of CYP3A4 and substrate of P-glycoprotein,
both drugs can seriously affect the pharmacokinetics of
co-administered drugs that are CYP3A substrates and/or
transported by P-glycoprotein.
Many of the commonly prescribed cardiovascular and
antibiotic therapies are incompatible with BOC and TVR
protease inhibitor therapy. Oral contraception cannot be
relied upon as an effective method of contraception,
which is mandatory given the known teratogenicity of
the current triple therapy. Drug-interaction studies in
patients receiving TVR or BOC were conducted with the
following compounds : CYP3A4/5 inhibitors, such as
clarithromycin, ketoconazole, and ritonavir ; a
CYP3A4/5 inducer i.e., efavirenz ; CYP3A4/5 sub-
strates, such as midazolam, tenofovir ; class Ia or III anti-
arrhythmics and oral contraceptives. Different pharma-
cokinetic and/or pharmacodynamic interactions were
found that indicated the following : potential safe co-
administration (e.g., PPI) ; recommendations to assess
the benefit/risk-ratio to justify drug co-administration ;
monitoring of drug levels (e.g., digoxin) or clinical
effects (e.g., clarithromycin) or intake prohibition of
 certain drugs together with DAAs (i.e., class Ia or III
anti-arrhythmics) (44, 46, 48). This interaction informa-
tion can be examined at the following web address :
www.hep-druginteractions.org.
Given this background, ALL PATIENTS WHO ARE
ELIGIBLE FOR TVR AND BOC TREATMENT MUST
BE SCREENED FOR DRUG-DRUG INTERACTIONS
before initiating their treatment plan. Patients and
 primary care givers need to be informed about these
interactions. 
Contraindications to therapy
Interferon-containing regimens :
Therapy with interferon-containing regimens has an
absolute contraindication in the following groups :
uncontrolled depression, psychosis, epilepsy, uncon-
trolled autoimmune diseases, decompensated cirrhosis
(i.e., Child-Pugh B7 or more), pregnant women, couples
unwilling to comply with adequate contraception,
uncontrolled hypertension, heart failure, poorly con-
trolled diabetes, severe chronic obstructive pulmonary
disease, and other severe concurrent medical diseases.
Relative contraindications are as follows : abnormal
hematological values (i.e., hemoglobin < 13 g/dL for
men and < 12 g/dL for women ; neutrophil count
< 1500/mm3 ; and platelet count < 90,000/mm3) ; serum
creatinine level > 1.5 mg/dL ; significant coronary heart
disease ; and untreated thyroid diseases. Although
decompensated cirrhotic patients should not be treated,
treatment of patients with Child-Pugh B cirrhosis may be
feasible under careful monitoring in experienced trans-
plant centers.
Boceprevir and Telaprevir :
Because BOC and TVR cannot be prescribed without
interferon, contraindications to interferon-containing
regimens are applicable to BOC- and TVR-treated
patients. Because both drugs exacerbate hematological
side effects (in particular anemia), attention to baseline
hematological values is mandatory.
Which G1 patients are unsuitable for triple therapy ?
All HCV genotype 1 patients with compensated liver
disease who are willing to be treated and without con-
traindication to pegIFN and RBV should be considered
for therapy. Treatment should be initiated promptly in
patients with advanced fibrosis (i.e., METAVIR scores
F3-F4) and strongly considered in patients with moder-
ate fibrosis (i.e., METAVIR score F2). In patients with
less severe disease, indication for therapy is on an indi-
vidual basis.
Special populations
Patients with renal failure : HCV patients with renal
failure were excluded from the BOC and TVR stud-
ies (16,17,19,21). Therefore, because those patients are
at increased risk of ribavirin-induced anemia, triple
 therapy with first-generation DAAs should be avoided
until data are available. The patients with renal failure
and particularly end-stage renal disease patients should
be treated with pegIFN and an adapted schedule of RBV
in conjunction with an optimal use of erythro -
poietin (49,50).
Transplanted HCV patients : HCV reinfection is
almost universal in HCV RNA-positive patients at the
time of transplantation and significantly impairs patient
and graft survival. Treatment of established HCV recur-
rence with pegIFN and RBV allows SVR in approxi-
mately 30% of the patients. Therefore, patients with
HCV recurrence after transplantation are those who will
benefit the most from direct antiviral agents. However,
pharmacokinetic studies suggest that co-administration
of first-generation DAAs with either cyclosporine or
tacrolimus markedly increase exposure of both immuno-
suppressants (48). Moreover, results of BOC and TVR
therapies in transplanted patients are not yet available.
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3. HCV genotype 1 patients with no or mild fibrosis
BOC and TVR-based triple therapy represent a major
step in the management of chronic hepatitis C patients by
dramatically increasing the SVR rate. However, these
regimens need strict compliance and induce additional
side effects. More potent and better tolerated second-
generation DAAs that have less complex pharmacokinet-
ic profiles are in phase III studies and will be available
soon (55). Therefore, prior to initiating BOC and TVR-
based triple therapy, it is important to identify those
patients who are highly likely to respond to such therapy,
in particular HCV patients with no or mild fibrosis
because these patients could wait for second-generation
DAAs. The characteristics associated with a reduced
SVR rate have been reported in BOC and TVR phase III
studies (16-19,21). A reduction in the HCV RNA level of
< 1 log10 after a 4-week lead-in period is a significant fac-
tor that is associated with reduced SVR. Other factors
associated with lower SVR are as follows : previous non-
response to pegIFN + RBV (i.e., prior null response
mainly and prior partial response) ; high baseline HCV
RNA levels (i.e., > 800.000 IU/mL in most studies) ;
presence of advanced fibrosis or cirrhosis ; unfavorable
IL-28B genotype (i.e., CT/TT) ; age > 40-45 ; genotype
1a ; high BMI (> 30) ; ethnic origin (black vs. non-
black) ; and presence of type 2 diabetes. All of these fac-
tors must be considered before deciding to initiate thera-
py with BOC- and TVR-based triple therapy.
What do we absolutely avoid with first-generation
DAAs ?
Clinical practice will change with the use of triple
therapies. The following principles are important to con-
sider to prevent the risk of resistance development and
futile exposure to first-generation DAAs.
First-generation DAAs and non-genotype 1
BOC and TVR are only recommended in genotype 1
HCV patients and cannot be prescribed in other geno-
types. Although TVR has demonstrated some efficacy
against genotype 2 patients, no or very limited efficacy
has been observed in genotypes 3 and 4 HCV
patients (56). Optimistic results with a second-wave pro-
tease inhibitor have been observed in HCV patients with
genotypes 2, 4, 5 and 6, but these preliminary results
must be confirmed (57).
DAA monotherapy
Phase I studies with DAA monotherapy have been
associated with rapid viral breakthrough because of the
rapid development of resistant variants (26). Therefore,
DAA monotherapy is strictly prohibited.
DAA + pegIFN without RBV
In the PROVE 2 study, one arm received pegIFN +
telaprevir without RBV. This arm deonstrated very low
probability of SVR (30). Therefore, initiating therapy
with pegIFN + BOC or TVR without RBV must be
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For these reasons, BOC and TVR therapies should not be
recommended in transplanted patients until data are
available.
HIV-HCV coinfected patients : HCV has become a
major cause of morbidity and mortality among HIV
patients. HIV/HCV coinfected patients have a higher
baseline viral load, more rapid progression of liver dis-
ease and less chance of SVR compared with HCV mono-
infected patients. Preliminary results of BOC and TVR
combined with pegIFN and RBV in treatment naïve
genotype 1 chronic HCV patients who are HIV co-infect-
ed have been demonstrated to be safe and exhibit signif-
icantly higher SVR rates compared with pegIFN and
RBV alone (51,52). However, more data, particularly
regarding drug-drug interactions and efficacy results in
previously nonresponder HCV/HIV co-infected patients
are required before routinely treating genotype 1 HCV
patients who are HIV co-infected with boceprevir and
telaprevir.
Unfavorable baseline characteristics
1. Null responders with mild or moderate fibrosis
The most difficult to treat group of patients, who are
prior null responders to pegIFN and RBV, were only
specifically studied in the REALIZE trial (21). Although
there was an improved outcome in these patients with
TVR-based triple therapy compared with pegIFN +
RBV, the SVR rate was only 29 to 33%. Furthermore,
relapse rates were high and virological failure rates were
higher, which was predominantly because of the emer-
gence of resistant variants. Similar SVR rates have been
observed in prior null responders who were treated with
BOC-based triple therapy in a study that was presented
in abstract form (20). Although this therapeutic result is
an improvement over previous therapies, SVRs are like-
ly to remain low in prior null responders. Treating these
patients with first-generation DAAs risks the increased
development of resistance mutants, which potentially
jeopardizes the use of future DAAs. For these reasons, it
is better to wait to treat these patients with future DAAs
(with a higher barrier to resistance) or by combining two
DAAs (53). 
2. Null responders with advanced fibrosis and cirrhosis
In the REALIZE trial, SVR rates in the subgroup of
null responders with advanced fibrosis or cirrhosis who
were treated with TVR-based triple therapy were
between 22 to 28% (21). However, these patients are at
high risk of developing complications in the short
term (54) before more potent DAAs or DAA combina-
tions become available. Therefore, such patients ideally
should be retreated within a randomized control trial set-
ting with next-generation DAA regimens. When retreat-
ed outside of the context of clinical trials, the futility
rules in case of virological failure must be followed to
limit excessive costs and the risk of emergence of resist-
ant variants.
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avoided. However, if severe anemia occurs during triple
therapy, it appears that RBV can be safely discontinued
once the HCV RNA level is undetectable.
Do not reinitiate DAA treatment once discontinued
If BOC or TVR treatment requires to be discontinued
during therapy for safety issues, reinitiating DAA treat-
ment is strictly prohibited.
Do not reduce dose of DAA
An adequate dose of BOC (800 mg 3 times per day)
and TVR (750 mg 3 times per day) must be prescribed.
Dose reductions are strictly prohibited to avoid resistant
variant development and reduced efficacy. If DAA-relat-
ed severe safety issues occur during therapy, DAA may
require termination, but never a dose reduction or reini-
tiated treatment once discontinued.
Do not retreat with another first-generation Protease
Inhibitor
In cases of virological failure to BOC or TVR, resist-
ant variants are frequently detected. The resistance
 profiles are very similar between boceprevir and telapre-
vir (33) ; therefore, the treatment of a nonresponder to
one first-generation DAA with another first-generation
DAAs is strictly prohibited.
Side effect management
New challenges arise with regard to managing DAA-
specific side effects that might partially offset the effec-
tiveness of these new agents in clinical practice. In par-
ticular, anemia, neutropenia, dysgeusia, anorectal pain
and cutaneous manifestations, were significantly more
frequently experienced by patients receiving triple thera-
py in all of the phase 3 trials (16,17,19,21). Only adverse
events with incidences greater or equal to 10% were
reported.
Anemia (defined as hemoglobin < 10 g/dL)
The mechanism of anemia with both BOC and TVR is
thought to be the result of a bone marrow suppressive
effect (16,44,46). Therefore, surveillance by performing
a complete blood count before treatment, at weeks 2, 4,
6, 8 and 12, and monthly thereafter is advisable.
Anemia was the most significant adverse event asso-
ciated with BOC-containing regimens. Approximately
one-half (49%) of the BOC-treated subjects in the
SPRINT-2 trial had anemia (vs. 29% in the pegIFN/RBV
group), whereby 43% of the BOC-treated subjects
required erythropoietin (EPO) administration (vs. 24%
in the pegIFN/RBV group) (16). Despite the use of EPO,
a mean change in the hemoglobin level was observed
from week 12 and showed approximately a 4-point
decrease. Multivariate logistic regression analysis identi-
fied female sex (OR 1,9) and an age > 40 (OR 0,4) as
 significant baseline factors associated with developing
anemia upon BOC treatment (16).
Anemia was observed in 37% of the TVR-treated sub-
jects, (vs. 19% in the pegIFN/RBV group). In contrast to
BOC, EPO was disallowed in studies with TVR, which
led to the discontinuation of TVR because of anemia in
1-3% and of the entire treatment in 1% of patients (17,
21,46,47).
How do we manage anemia due to DAAs in
Belgium ? Because EPO is not reimbursed in this indica-
tion in Belgium, symptomatic anemia is controlled by
reducing the ribavirin dose if the hemoglobin concentra-
tion decreases to < 10 g/dL. In the era of pegIFN/RBV
treatment, this strategy was shown only to have a nega-
tive effect on SVR when the cumulative dose is <60% of
the initially planned dose and/or at a moment when HCV
RNA level was still detectable (58). Within the context
of triple therapy, a recent retrospective analysis of effica-
cy outcomes based on anemia and RBV dose reduction
in the ADVANCE and ILLUMINATE trials confirmed
that RBV dose reduction did not effect SVR with TVR-
based therapy (59). In a similar retrospective analysis of
BOC-treated patients, higher SVR rates were observed in
patients who developed anemia, but because 80% of the
studied patients took EPO, the relationship SVR, dose
reduction of RBV and EPO usage was less clear (60).
Based on the available data, it may be reasonable to
maintain the full dose of RBV until the HCV RNA level
becomes undetectable. If symptomatic anemia does
occur or when the HCV RNA level is undetectable in
other cases, the daily RBV dose may be reduced by 200-
mg increments while not exceeding a reduction of > 60%
of the initially planned dose. The DAA dose should
never be reduced. However, RBV treatment should be
interrupted if the hemoglobin level is less than 8.5 g/dL.
At this point, all three treatments (i.e., pegIFN/RBV and
DAA) should be discontinued.
Neutropenia
Neutropenia was reported to be more common in
patients receiving triple therapy with BOC compared to
combination pegylated interferon and ribavirin alone (23
vs. 18%). Severe infections were, however, infrequent,
and treatment cessation was rarely warranted. Close
monitoring clinically and by full blood count (cfr ane-
mia) is advisable (16,19,44).
Dysgeusia
Dysgeusia is described as a metallic taste in the mouth
and has been reported in treatment with pegIFN-RBV.
Although not considered a serious adverse event, dys-
geusia occurred twofold more frequently in BOC-treated
patients compared with control-treated patients. In the
SPRINT-2 trial, 37-43% of the BOC-treated patients
experienced this side effect (16), and similar rates were
reported in the RESPOND-2 trial (19). This adverse
event apparently occurs throughout the entire treatment
and contributes to the problem of anorexia and major
weight loss often caused by interferon. There is no
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will oblige practitioners to know more on this specific
topic (46, 47, 62).
Skin toxicity is the most frequent and important side
effect associated with TVR therapy. Over 50% of the
TVR-treated patients developed rash compared with
33% in the placebo group. The median time to any rash
event was approximately a month. The specific defini-
tions of the different grades of TVR-associated rash
(Fig. 3) and their management are summarized in
Table 5. It was observed that the dermatological mani-
festations with TVR-based therapy are generally similar
in type to the reactions observed with pegIFN-RBV
treatment, but the median time to a grade 3 event was
7 weeks. Ninety percent of rashes were confined to
grades 1 or 2. Rash as a serious adverse event occurred
exclusively in the TVR group and led to the permanent
discontinuation of TVR in 6-7% of treated patients in
phase II trials. Notably, this figure declined to 1% in the
phase III trials after installing a rash management plan
that emphasized the usefulness of early recognition and
intervention (46,47,62).
A number of severe cutaneous adverse reactions
occurred during the TVR development program, includ-
ing Stevens Johnson syndrome and DRESS syndrome
(drug reaction with eosinophilia and systemic symp-
toms). All treatment is to be discontinued in these situa-
tions. Therefore, a patient with a cutaneous reaction that
is unlike the HCV treatment-associated rash should be
assessed for signs that may suggest severe skin toxicity,
such as DRESS or Steven Johnson syndrome.
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 specific treatment for dysgeusia, but it disappears on dis-
continuation of triple therapy.
Gastrointestinal
A TVR-specific side effect is anorectal discomfort
(i.e., rectal burning and pruritus) which was experienced
by 29% of the TVR-treated subjects versus 7% of the
control subjects. The onset is typically during the first
2 weeks of treatment. The mechanism is unexplained but
may relate to metabolites that are excreted in feces.
There is no relationship with generalized pruritus or skin
rash. A proctological exam usually shows nonspecific
erythema without other lesions.
Treatment with a topical steroidal ointment with
betamethasone (i.e., twice daily for 10 days, followed by
once daily for 10 days and then every other day for
another 10 days) and a systemic antihistamine are con-
sidered beneficial. The symptoms resolve completely
after TVR withdrawal but rarely impose an early discon-
tinuation of therapy (46,47,61).
Dermatological adverse events
Dermatological adverse events can be a concern dur-
ing HCV infection (e.g., porphyria cutanea tarda, lichen
planus, and pruritus) or pegIFN-RBV treatment. During
pegIFN-RBV treatment, the dermatological manifesta-
tion tends towards a uniform presentation of dermatitis
that is characterized by skin xerosis with eczematiform
lesions. The introduction of DAAs in clinical practice
Fig. 3. — Dermatological side effects
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Moreover, all patients on DAAs are advised to apply
“good skin care practice”. Emollient creams and lipid-
rich lotions are effective as prophylactic baseline skin
treatments. Proper skin care takes approximately 15 min-
utes and should be implemented in a daily routine.
Therapy is best employed after a shower or bath when
the skin is well hydrated. Cacoub et al. provide a detailed
review of dermatological side effects (62).
Conclusions and future perspectives
By understanding dosing and administration instruc-
tions, treatment durations, response-guided therapy and
futility rules, clinicians have two new and effective anti-
HCV treatment regimens for genotype 1 patients. To opti-
mize patient outcomes, awareness of possible interfering
drug-drug interactions and experience in side effect
 management of pegIFN-RBV therapy and additional new
protease inhibitor-related toxicities is required.
The current guidelines are based on collected data that
are presently limited. Accordingly, a reconsideration of
some of the recommendations may be required as
 additional data become available. Ideally, treatment
schedules and recommendations on HCV RNA monitor-
ing and futility thresholds should be comparable across
future DAA treatment regimens. 
The pegIFN and RBV combination therapy has con-
sistently demonstrated its importance in reducing viral
load and suppressing viral breakthrough with the cur-
rently approved first-generation protease inhibitors BOC
and TVR. PegIFN-RBV-protease inhibitor triple combi-
nation therapy can be associated with considerable, often
treatment-limiting toxicity. Therefore, the ultimate goal
of a short, highly effective and well-tolerated treatment
has not been achieved for patients with chronic HCV
infection. New protease inhibitors allow once daily dos-
ing (63) and are under evaluation in phase III trials.
Once-daily dosing will enhance treatment compliance.
Combinations of DAAs with different modes of action
and pegIFN and RBV may further improve SVR rates or
shorten therapy duration (64,65). Exploratory studies
with pegIFN and RBV that provide combination regi-
mens in humans have been initiated. PegIFN-free combi-
nations of a protease inhibitor with a nucleoside poly-
merase inhibitor (66), a nonnucleoside polymerase
inhibitor (67), and a nonstructural viral protein 5A
(NS5A) inhibitor (53,68) have yielded promising short-
term antiviral efficacy in genotype 1 patients. Acceptable
side effect profiles of these new DAA molecules when
used in mono- and combination therapies are required to
advance through the clinical trial phases. Viral resistance
to DAA is another challenge to successfully treating sub-
type 1a-infected patients because these patients seem
more prone to resistance. Ultimately, regimens that com-
bine multiple DAA with favorable side effect profiles
may overcome IFN nonresponsiveness in null respon-
ders by increasing antiviral activity and reducing the risk
of resistance-associated variants. These types of progress
increase the expectation that HCV infections could be
eradicated in the near future.
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Table 5. — Dermatological side effects and management plan
The “Rule of nines” estimates body surface area using estimates of 9% : arm 9%, head front and back 9%, leg 18%, chest 18%, back 18%, and
 perineum 1% (69).
Grade of Telaprevir-
associated rash
Description Management
Grade 1 (mild) localized skin eruption and/or a skin eruption with
limited distribution (up to several isolated sites on the
body) with or without associated pruritus 
– Use topical class 3 potent corticosteroids
– systemic antihistaminic drugs for associated pruritus
– Limit exposure to sun/heat and wear loose-fitting
clothes
– monitor for progression or systemic symptoms
until the rash is resolved
Grade 2 (moderate) diffuse rash involving ≤ 50% of body surface area
(according to the “rule of nines”) with or without
superficial skin peeling, pruritus, or mucous membrane
involvement with no ulceration
– Same as for grade 1
– consider dermatological advice
– if a moderate rash progresses, permanent
discontinuation of telaprevir should be considered 
Grade 3 (Severe) Generalized rash involving either extent of rash > 50%
of body surface area OR
Rash presenting with any of the following
characteristics :
– vesicles or bullae
– superficial ulceration of mucous membranes
– epidermal detachment
– atypical or typical target lesions
– palpable purpura/non-blanching erythema 
– Permanently discontinue telaprevir immediately
– Consultation with a specialist in dermatology is
recommended
– Monitor for progression or systemic symptoms until
the rash is resolved
– If no improvement within 7 days of stopping
telaprevir (or earlier if rash worsens), sequential or
simultaneous interruption or discontinuation of
ribavirin and/or peginterferon should be considered
Severe Cutaneous Adverse
Reaction (SCAR)
Collective term for severe drug-related skin conditions
that can be associated with significant morbidity :
Stevens-Johnson syndrome, toxic epidermal necrolysis
(TEN) , drug reaction with eosinophilia and systemic
symptoms (DRESS), erythema multiforme, acute
generalized exanthematous pustulosis (AGEP)
Permanent and immediate discontinuation of
telaprevir, peginterferon and ribavirin is required
Consult with a specialist in dermatology
Admit for IV fluids, systemic treatment and observation
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